Lupus Foundation of America Drives Nationwide Effort to Make Lupus Visible During Lupus Awareness Month

AUPH Stock  USD 9.20  0.22  2.45%   
Under 70 percent of all Aurinia Pharmaceuticals' traders are curious in acquiring. The analysis of the overall investor sentiment regarding Aurinia Pharmaceuticals suggests that a large number of traders are confidant. Aurinia Pharmaceuticals' investing sentiment shows overall attitude of investors towards Aurinia Pharmaceuticals.
  
During Lupus Awareness Month in May, the Lupus Foundation of America will bring communities together to raise awareness of the disease that affects millions worldwide, and generate funds to bolster lupus research, educational programs and support services.

Read at finance.yahoo.com
Yahoo News
  

Aurinia Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Aurinia Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Aurinia Pharmaceuticals Fundamental Analysis

We analyze Aurinia Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aurinia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aurinia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Per Share

Cash Per Share Comparative Analysis

Aurinia Pharmaceuticals is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Aurinia Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aurinia Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aurinia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aurinia Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Aurinia Pharmaceuticals Related Equities

BTAIBioXcel Therapeutics   6.43   
0%
100.0%
TGTXTG Therapeutics   1.15   
0%
17.0%
MDGLMadrigal Pharmaceuticals   0.30   
4.0%
0%
EXELExelixis   0.65   
10.0%
0%
PTCTPTC Therapeutics   1.33   
20.0%
0%
AXSMAxsome Therapeutics   1.44   
22.0%
0%
SRPTSarepta Therapeutics   1.52   
23.0%
0%
TERNTerns Pharmaceuticals   1.87   
29.0%
0%
AKROAkero Therapeutics   2.22   
34.0%
0%
VKTXViking Therapeutics   2.81   
43.0%
0%
MCRBSeres Therapeutics   3.61   
56.0%
0%
HEPAHepion Pharmaceuticals   4.00   
62.0%
0%

Complementary Tools for Aurinia Stock analysis

When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Transaction History
View history of all your transactions and understand their impact on performance
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Equity Valuation
Check real value of public entities based on technical and fundamental data
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories